Handok's new rare disease drug ‘Doptelet (avatrombopag)' was approved in Korea on the 26th.

The Ministry of Food and Drug Safety approved Doptelet as a treatment for thrombocytopenia for patients with liver disease.

Handok is reaping the benefits of forging a strategic partnership with the global biopharmaceutical company Sobi-Handok last year.

At that time, the company decided to introduce two new drugs, Empaveli (pegcetacoplan) and Doptelet, a rare disease treatment, into the country, both of which have now been approved in Korea.

Doptelet is an orally administered second-generation thrombopoietin receptor agonist (TPO-RA) approved in the U.S. for th